Novo Nordisk reported adjusted net sales of 70.1 billion Danish kroner ($11 billion) for the first quarter of 2026, down 4% year over year but still 1% above consensus estimates. The gain came from an early surge in its new oral obesity drug, the Wegovy pill. Launched in the U.S. on January 5 after late‑2025 approval, it generated about $355 million in its debut quarter. CEO Mike Doustdar said more than 1 million people have used the pill since launch, with 1.3 million prescriptions filled in Q1 and around 2 million by mid‑April. U.S. operations EVP Jamey Millar added that about 80% of Wegovy pill users were new to the GLP‑1 class. Shares rose roughly 3% after results were released on May 6.
Strong Wegovy pill uptake steadied investor sentiment after a volatile 2025 that saw leadership reshuffling and heavier GLP‑1 competition from Eli Lilly. Novo’s success in turning an oral formulation into a growth engine shows that its expansion beyond injectables was more than a gamble, it was a strategic pivot that worked. The momentum partly masked what analysts called a “notable miss” on insulin revenue and reinforced how patient preference for oral agents, plus the easier access they allow, is quietly rewriting the obesity market’s economics.
The next hurdle is endurance. Demand must hold up once early stocking eases and those first‑wave patient switchovers settle. Lilly’s Foundayo, launched in April, will test Novo’s pricing discipline and payer leverage through mid‑2026. If Novo keeps its “sweet spot” pricing intact, category leadership and margin stability remain within reach, though payer scrutiny is rising fast. PBM and employer plan observers will be watching closely; the first real data on GLP‑1 formulary flows from these oral launches arrives this summer. (Personally, I suspect that’s when we’ll learn who’s bluffing on access.) For a deeper look at PBM reimbursement exposure, see RxPBM.ai.
